Research and Markets: Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/k7lbzb/eluxadoline) has announced the addition of the "Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023" report to their offering.

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Eluxadoline is being developed for the treatment of IBS-D. As of October 2014, it had reached the Phase III stage of development, and also has been granted a Fast-Track designation by the FDA. Furiex Pharmaceuticals initially licensed eluxadoline from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson [J&J]) for the development of the product. Subsequently, Furiex was fully-acquired by Actavis in July 2014 (Furiex Pharmaceuticals, press release, July 2, 2014).

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Classification

3.3 Symptoms

3.4 Prognosis

3.5 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

4.1.2 Treatment Guidelines and Leading Prescribed Drugs

4.1.3 Clinical Practice

5 Competitive Assessment

6 Unmet Need and Opportunity

6.1 Overview

6.2 More Effective Pharmacotherapies

6.3 Therapies for the IBS-D Subtype

6.4 Therapies for the IBS-M Subtype

6.5 Therapies to Address Abdominal Pain and Bloating Symptoms

6.6 Improved Diagnosis Rate for IBS

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

8 Eluxadoline

9 Appendix

For more information visit http://www.researchandmarkets.com/research/k7lbzb/eluxadoline

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals